Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00706641 · ClinicalTrials.gov registry record · NA
Neoadjuvant Dasatinib and Radical Cystectomy for Transitional Cell Carcinoma of the Bladder
A NA study, sponsored by Hoosier Cancer Research Network.
- Completed
- Registry status
- NA
- Development phase
- 25
- Enrollment target
NCT00706641: Completed NA study, sponsored by Hoosier Cancer Research Network.
NCT00706641 is a NA study that has completed, run by Hoosier Cancer Research Network. The registered enrollment target is 25 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00706641, a NA study, has completed, sponsored by Hoosier Cancer Research Network.
- COMPLETED
- Registry status
- NA
- Development phase
- 25 participants
- Enrollment target
Study Summary
This pilot study is designed to determine feasibility and safety of treatment with dasatinib administered orally once daily for 4 weeks duration prior to radical cystectomy for urothelial carcinoma of the bladder.
Primary Outcome
Feasibility for this trial is defined as at least 60% (\>=14 of 23) of patients completing study therapy in the absence of Dose Limiting Toxicity (DLT)
Interventions
- DRUG Dasatinib
- PROCEDURE Radical Cystectomy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2008-06 |
| Est. Completion | 2012-12 |
| Phase | NA |
What the finished NCT00706641 record still lists
NCT00706641 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Dasatinib is the first listed.
NCT00706641 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00706641 about?
NCT00706641 is a clinical study titled "Neoadjuvant Dasatinib and Radical Cystectomy for Transitional Cell Carcinoma of the Bladder". This pilot study is designed to determine feasibility and safety of treatment with dasatinib administered orally once daily for 4 weeks duration prior to radical cystectomy for urothelial carcinoma of the bladder.
What is the current status of trial NCT00706641?
This trial is currently completed. It is a NA study. The enrollment target is 25 participants. The study started on 2008-06. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00706641?
The interventions under investigation include: Dasatinib (DRUG), Radical Cystectomy (PROCEDURE).
Who is sponsoring clinical trial NCT00706641?
This trial is sponsored by Hoosier Cancer Research Network, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00706641's enrollment target sits among peer trials
25 1712th of 2000 higher than 265 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia